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Abstract 
To prevent complications that might follow an infection with varicella-zoster virus (VZV), the live 
attenuated Oka strain (V-Oka) is administered to children in many developed countries. Three vaccine 
brands (Varivax from Sanofi Pasteur MSD; Varilrix and Priorix-Tetra, both from Glaxo-Smith-Kline) are 
licensed in Germany and have been associated with both different degrees of vaccine effectiveness 
and adverse effects. To identify genetic variants in the vaccines that might contribute to rash-
associated syndromes, single nucleotide polymorphism (SNP) profiles of variants from the three 
vaccines and rash-associated vaccine-type VZV from German vaccinees were quantitatively 
compared by PCR-based pyrosequencing (PSQ). The Varivax vaccine contained an estimated 3-fold 
higher diversity of VZV variants, with 20% more wild-type (wt) SNPs than Varilrix and Priorix-Tetra. 
These minor VZV variants in the vaccines were identified by analyzing cloned full-length open reading 
frame (ORF) orf62 sequences by chain termination sequencing and PSQ. Some of these sequences 
amplified from vaccine VZV were very similar or identical to those of the rash-associated vaccine-type 
VZV from vaccinees and were almost exclusively detected in Varivax. Therefore, minorities of rash-
associated VZV variants are present in varicella vaccine formulations, and it can be concluded that the 
analysis of a core set of four SNPs is required as a minimum for a firm diagnostic differentiation of 
vaccine-type VZV from wt VZV.  
 
Introduction 
The varicella-zoster virus (VZV) live attenuated Oka strain (V-Oka) is licensed in developed countries 
for vaccination against varicella. In Germany, routine vaccination of healthy children >11 months of 
age has been performed since 2004. Since then, varicella morbidity has declined (16). The mixtures of 
V-Oka strains with different single nucleotide polymorphism (SNP) profiles present in vaccine 
preparations and the reported genomic variation of vaccine VZV strains have prompted investigations 
of the linkage of certain genomic variants to episodes of vaccine-induced rash (9, 10).  
We aimed at comparing the SNP profiles of the varicella vaccines used in Germany and of vaccine-
type VZV from German vaccinees for several reasons. First, three vaccine brands are distributed in 
Germany (Varivax from Sanofi Pasteur MSD [SPMSD], Leimen, Germany; Varilrix and Priorix-Tetra, 
both from GlaxoSmithKline [GSK], Munich, Germany) and have been associated with different 
degrees of vaccine effectiveness (17). In addition, data from the German varicella sentinel (16) 
indicated that the vaccines might be related to different frequencies of rash-associated syndromes, 
i.e., mild forms of varicella or zoster (Anette Siedler and Bernhard Ehlers, unpublished data). Second, 
vaccine-type VZV strains causing rash-associated clinical syndromes in vaccinees have been reported 
to contain a number of wild-type (wt) SNPs. It has been hypothesized that these vaccine-type, wt 
SNP-containing VZV strains are minor components of the vaccines (1, 9, 10, 13). To substantiate this 
hypothesis and to search for genetic correlates of the observed differences among the vaccines, we 
  
compared the SNP profiles of (i) VZV from the three vaccine brands, (ii) rash-associated vaccine-type 
VZV from German vaccinees, and (iii) wt VZV from nonvaccinated and vaccinated individuals suffering 
from varicella by PCR, quantitative pyrosequencing (PSQ), and chain termination sequencing (CTSQ). 
In addition, open reading frame (ORF) orf62 sequences were cloned in Escherichia coli and analyzed 
by the same methods.  
 
Materials and Methods 
Sample collection, vaccines, and DNA extraction. Vesicle material from vaccinees with varicella-
like rash or herpes zoster was collected as part of the varicella sentinel in Germany (16). Three 
vaccines from two manufacturers were analyzed: Varivax (monovalent, lots NA28970 and HW08500) 
from SPMSD (Leimen, Germany) and Varilrix (monovalent, lot A70CA216B) and, with the same VZV 
component, Priorix-Tetra (tetravalent; lot A71CA024A) from GSK (Munich, Germany). DNA was 
extracted using a DNeasy blood and tissue kit (Qiagen, Hilden, Germany) according to the 
manufacturer's instructions.  
LD-PCR and sequence analysis. Long-distance PCR (LD-PCR) was performed as follows: the 
reaction mixture was set up on ice and contained 50 μl of ExTaq buffer with MgCl2, 400 μM each 
deoxynucleoside triphosphate (dNTP), 400 nM each primer, and 2.5 units of ExTaq polymerase 
(TaKaRa Bio Inc., Japan). Thirty cycles of amplification were performed, with each cycle consisting of 
a denaturing step at 98°C for 20 s, an annealing step at 63°C for 30 s, and an elongation step at 72°C. 
The duration of the elongation step was 7 min in the first 15 cycles and 10 min plus a 5-s ramp time for 
each of the last 15 cycles. The final elongation step was performed for 30 min at 72°C. LD-PCR was 
performed in a nested format using primer pairs LD_a1 and LD_a2 in the 1st and 2nd rounds (Table 
1). When no PCR product was obtained (because of very low copy number), the three alternative 
primer pairs, LD_b1, LD_b2, and LD_b3, were used (Table 1).  
PCR products were purified with an Invisorb Spin PCRapid kit (Invitek, Berlin, Germany) and directly 
sequenced by CTSQ using a BigDye Terminator cycle sequencing kit and an ABI Prism genetic 
analyzer (Applied Biosystems) according to the manufacturer's instructions. The programs DNAStar 
Lasergene (version 8) and MacVector (version 10.6) were used to examine the SNPs by comparing 
the obtained sequences with those of reference strains.  
When patient specimens were nearly exhausted, DNA was expanded in toto with a GenomiPhi 
(version 2) DNA amplification kit (GE Healthcare Life Sciences, Munich, Germany) according to the 
manufacturer's instructions. The qualitatively and quantitatively correct reamplification of VZV DNA 
and VZV variant mixtures from specimens with the GenomiPhi kit had been previously controlled using 
quantitative real-time PCR, conventional PCR, CTSQ, and PSQ (Judit Küchler and Bernhard Ehlers, 
unpublished data).  
Cloning in E. coli. PCR products spanning the complete orf62 (approximately 4 kb) and short PCR 
products containing a single SNP (<0.3 kb) were transformed into chemically competent E. coli cells 
using a TOPO-TA cloning kit (Invitrogen, Karlsruhe, Germany) according to the manufacturer's 
instructions. The plasmids containing the 4-kb inserts were extracted with a QIAprep spin miniprep kit 
(Qiagen, Hilden, Germany) and analyzed by cycle sequencing (see above). The plasmids containing 
the short inserts were tested with colony PCR and pyrosequencing (see below).  
PCR-based pyrosequencing. PSQ (12) was used for analyzing the allele frequency of VZV SNPs. 
Thirty-two PSQ assays, each consisting of a primer pair (with one primer biotinylated) for PCR (to 
generate a product containing the SNP of interest) and a separate sequencing primer, were designed 
by using the pyrosequencing assay design software (Biotage, Uppsala, Sweden) (Table 2). Each PCR 
mixture contained 35 μl of AmpliTaq Gold buffer, 2.0 mM MgCl2, 200 μM each dNTP, 1 μM each 
primer, 1.5 units of AmpliTaq Gold (Applied Biosystems), and DNA extracted either from vaccines 
(adjusted to 105 VZV genome copies per reaction setup) or from vaccinated individuals. Forty-five 
cycles of amplification were performed after enzyme activation at 95°C for 12 min. Each cycle 
consisted of a denaturing step at 95°C for 30 s, an annealing step at an appropriate temperature 
(Table 2) for 30 s, and an elongation step at 72°C for 60 s. The final elongation step was done for 10 
min at 72°C.  
  
For analysis of single E. coli clones, colony PCR was performed using the PSQ primer pairs with the 
same reaction setup. Colonies were picked and transferred directly into the pyrosequencing PCR 
mixtures. Spare material of the colony was streaked on a grid plate for later countercheck.  
For PSQ, 30 μl of the PCR products was immobilized, denatured, and washed using a PyroMark 
Vakuum prep workstation (Biotage, Uppsala, Sweden). The single-stranded DNA was transferred into 
a 96-well optical reaction plate (PSQ 96 Plate low; Biotage, Uppsala, Sweden) containing an 
annealing buffer and a specific sequencing primer. The annealing of the primer was done at 80°C for 2 
min. After cooling down of the reaction mixture, PSQ was performed at room temperature on the 
PyroMark ID apparatus (Biotage, Uppsala, Sweden). The resulting pyrograms allowed qualitative and 
quantitative SNP analysis. Quantification was conducted by PSQ software and is based on the fact 
that PSQ peak heights are proportional to the frequency of an allele in the sample. Therefore, PSQ 
peak heights provide an accurate measure of the proportion of VZV wild-type and vaccine-type alleles 
in a sample. In addition, the results of the analysis are presented in sequence context, confirming that 
the analysis was made at the correct sites. All PCRs plus PSQ measurements of the vaccines and the 
patient specimens with vaccine-type VZV were repeated two to four times.  
Reference strains. The VZV reference sequences used were those of strain Dumas (GenBank 
accession no. NC_001348), strain Oka-P (GenBank accession no. AB097933), Oka-V (GenBank 
accession no. AB097932), Varilrix (GenBank accession no. DQ008354), and Varivax (GenBank 
accession no. DQ008355).  
 
Results and Discussion 
As part of the German varicella sentinel (16), specimens from vaccinated individuals with rashes were 
subjected to VZV PCR and PSQ for differentiation between wt VZV and vaccine-type VZV by 
analyzing five SNP positions (nt 105544, 105705, 106262, 107252, and 108111; positions were based 
on the genome sequence of the Dumas strain). Between January 2004 and December 2010, 505 
specimens were found by PCR and sequencing to contain the VZV wt and 20 were found to contain a 
VZV vaccine type. Of the latter, 12 had been clinically diagnosed to originate from a varicella-like rash 
and 8 originated from herpes zoster (HZ) (Bernhard Ehlers and Annette Siedler, unpublished data). To 
comprehensively determine the frequency of wt alleles and their fraction in mixed alleles at SNP 
positions in these vaccine-type VZV isolates, SNPs (n = 32) present in the VZV genome were 
analyzed with a panel of PCRs and subsequent PSQ. The PCR and PSQ primers used are listed in 
Table 2. The specimens of nine vaccinees (vaccinees 1 to 9; Fig. 1, 2, and 3) contained enough VZV 
genome copies for this genome-wide SNP analysis. Those with low copy numbers (vaccinees 1 to 6) 
had to be expanded in toto as described in the Materials and Methods section to perform all analyses 
of this study. The remaining 11 specimens had such low copy numbers that not all PCR amplifications 
were successful. These were not included in the study. For comparison, the SNP profiles of wt VZV 
from nonvaccinated (n = 4) and vaccinated (n = 5) individuals suffering from varicella were analyzed 
by the same PSQ approach. Before the patient specimens were analyzed, the SNP profiles of VZV 
from the three varicella vaccines distributed in Germany (Varivax from SPMSD, Varilrix and Priorix-
Tetra from GSK) were quantitatively evaluated.  
Comparison of Varivax, Varilrix, and Priorix-Tetra vaccine VZV by PSQ. To get more detailed 
information about the SNP distribution in Varivax, Varilrix, and Priorix-Tetra vaccine VZV, we 
examined 32 SNP positions by PSQ. All SNP profiles were tabulated and compared to those of the 
previously published SNPs of Varivax and Varilrix VZV (18), the original vaccine strain Oka-V, as well 
as wt parent strain Oka-P (7) and the wt Dumas strain (3) (Fig. 1). To firmly discriminate pure wt and 
pure vaccine-type alleles from mixed alleles in the vaccines, the performance of all PSQ assays with 
specimens from nine patients infected with wt VZV was assessed. Here, we expected PSQ 
measurements of 100% wt and 0% vaccine-type alleles at all 32 SNP positions. In fact, only a part of 
the PSQ assays revealed 100% wt allele. The others revealed background signals in a highly 
reproducible fashion, falsely indicating the presence of the vaccine-type allele (data not shown). 
Therefore, we calculated individual limits of detection for the minority allele for all PSQ assays. To 
achieve this, the median height of the background signals obtained from the nine patients with wt VZV 
was calculated for 25/32 PSQ assays. For the remaining seven PSQ assays targeting SNPs at 
positions nt 560, 105310, 105544, 105705, 106262, 107252, and 108111, cloned VZV sequences 
were available (see below), and their pyrograms were used for calculation of the detection limits. The 
  
median of the peak height of the background signal plus 2-fold standard deviation was defined as the 
individual limit of detection for each assay. The resulting detection limits of up to 12% for the 32 
assays partially exceeded those of a previous study aimed at detecting mutant minorities of human 
cytomegalovirus. In that study, detection limits of 6% had been defined for four PSQ assays (15). In 
the present study, the detection limits of 19 assays were <6%, but those of 10 assays were >6% and 
those of 3 assays were >10%. The 13 assays with high detection limits were probably due to the high 
GC content of the VZV genome, which occasionally hampered the design of optimal PSQ assays. All 
PSQ values determined in our study which exceeded the detection limit of the respective PSQ assay 
were considered to represent true alleles (Fig. 1 to 4). 
The qualitative SNP profile of Varivax VZV determined here matched only at 20 SNP positions with the 
Varivax VZV profile published by Tillieux et al. (18). Similarly, the present SNP profiles of Varilrix and 
Priorix-Tetra VZV matched at only 18 positions the Varilrix VZV profile determined by these authors 
(18). Using the CTSQ methodology, they detected (with reference to the panel of 32 SNPs 
investigated in this study) 11 pure wt SNPs in Varivax VZV and 4 in Varilrix VZV. Here, we found only 
four pure wt SNPs in Varivax VZV and none in Varilrix or Priorix-Tetra VZV. In addition, 9 pure 
vaccine-type SNPs in Varivax VZV and 14 in Varilrix VZV had been detected by CTSQ. We identified 
only five pure vaccine-type SNPs in Varivax VZV, six in Varilrix VZV, and seven in Priorix-Tetra VZV 
(Fig. 1). In addition, some mixed SNPs revealing minority allele fractions of >20% in our study (Varivax 
VZV, nt 703, 763, 58595, and 107797; Varilrix/Priorix-Tetra VZV, nt 763, 19431, 31732, 71252, 87306, 
89734, 105310, and 107797) had not been identified to be mixed in earlier reports of studies using 
CTSQ (7, 10). Most likely, this indicates differences between vaccine batches (Fig. 1). It has already 
been noted that Varivax V-Oka has undergone some changes in variant content compared with that of 
the original Biken vaccine (9) (compare also Varivax VZV accession no. DQ008355 and V-Oka 
accession no. AB097932 in Fig. 1). This is underlined by the SNP profile of VZV from the Varivax lot 
analyzed in this study, which differs from both published vaccine VZV profiles (Fig. 1) and therefore 
indicates additional changes over time. Finally, we also identified mixed SNPs with wt allele fractions 
below 20%. These minor wt fractions had been missed by CTSQ (7, 10), most likely because the PSQ 
method is more sensitive and quantifies more accurately than CTSQ (12).  
A quantitative examination of all vaccine PSQ measurements was performed, and the percentages of 
wt alleles are plotted in Fig. 5. The data show nearly identical wt allele fractions in Varilrix and Priorix-
Tetra VZV strains. This was theoretically expected for all 32 SNPs since the VZV component in 
Priorix-Tetra is the same as that in Varilrix. In addition, the wt allele percentages of Varivax VZV 
measured by PSQ in this study were very similar to the PSQ values reported previously for Varivax 
VZV (10) (see Fig. S1 in the supplemental material). These data convincingly demonstrate the 
suitability of the PSQ technique for quantitative molecular typing of VZV. By comparing the three 
vaccines through quantification of the PSQ signals, we detected on average 54% wt alleles in Varivax 
VZV which exceeded the wt allele fractions in Varilrix and Priorix-Tetra VZV (both 35% wt alleles) by 
about 20% (Fig. 5).  
PSQ revealed 100% vaccine VZV markers at positions 560, 105705, 106262, 107252, and 108111 in 
all three vaccines. All other loci revealed mixed markers for Varilrix and Priorix-Tetra VZV (5 to 90% wt 
alleles) and Varivax VZV (11 to 90% wt alleles) except four loci in Varivax VZV, where only wt markers 
were detected (nt 12779, 31732, 89734, and 107599) (Fig. 5).  
SNP positions containing 100% vaccine VZV markers in vaccines as well as in vaccine-type VZV from 
vaccinees are suitable for differentiation between vaccine-type VZV and wt VZV in routine diagnostics. 
Pure (100%) vaccine VZV markers have been detected previously by PSQ at positions 560, 105705, 
106262, 107252, and 108111 in the Varivax vaccine VZV as well as in patient isolates (except SNP 
560) (10). In accordance, vaccine-type VZV alleles were also detected in our PSQ analysis, albeit with 
weak wt signals at positions 560 (5 to 9%) and 107252 (5 to 7%), just below the detection limits of 
10% and 8%, respectively (Fig. 5). To assay these SNPs in more depth, we analyzed all five positions 
by cloning the respective five PCR fragments from Varivax in E. coli K-12 and screened 73 to 125 E. 
coli clones per SNP position for inserts with wt alleles. One of 100 clones (1%) revealed the wt allele 
at position 560, 0/96 at position 105705, 7/125 (6%) at position 106262, 0/99 at position 107252, and 
4/73 (5%) at position 108111. This indicated very low wt allele minorities at positions 560, 106262, and 
108111 but not at positions 105705 and 107252. Likewise, the minor, mostly doubtful wt signals in 
Varilrix VZV at positions 105310, 105544, and 107136 were evaluated by cloning. Inserts with wt 
alleles were identified in 3%, 0%, and 4% of the clones, respectively. This confirmed very low wt allele 
minorities at positions 105310 and 107136 in Varilrix VZV (Fig. 1).  
  
SNP analysis of (i) vaccine-type VZV from vaccinees and (ii) wild-type VZV from nonvaccinated 
individuals and vaccinees with PSQ. In the nine specimens from vaccinees with vaccine-type VZV, 
five SNPs in orf62 homogeneously displayed the vaccine-type allele (nt 560, 105705, 106262, 
107252, and 108111), being in accordance (except nt 560) with the findings of previous analyses of 
vaccinees with rashes (6, 9, 10, 11). All specimens also displayed mixed alleles and therefore 
contained mixtures of variants (see below) (Fig. 1). The high variability of the mixed allele percentage 
(6.2 to 40.6%) may be in part due to the fact that the specimens contained highly different total VZV 
copy numbers (100 to 107) and that the firm determination of a minority allele is limited to specimens 
with a sufficient copy number. In addition, the samples were most likely derived from different numbers 
of lesions, which may have influenced the numbers of variants detected.  
At four positions (nt 12779, 31732, 107599, and 107797), all specimens revealed 100% wt alleles. 
This is in accordance with reports of previous studies that observed 90 to 100% wt alleles at these 
positions (9, 10). Furthermore, it largely matched the Varivax VZV profile (100% wt allele at positions 
12779, 31732, and 107599; 52% wt allele at nt 107797) rather than the profiles of the GSK vaccines, 
which uniformly revealed mixed markers (Fig. 1).  
The remaining 23 SNPs of the specimens displayed vaccine, wt, or mixed markers, apparently in a 
random fashion. There was no specimen that revealed wt alleles in all 23 variable positions 
(maximum, 18/23 for specimen no. 8) (Fig. 1). The percentage of wt markers in the different 
specimens varied by between 34% and 69%, and that of mixed markers varied by between 6% and 
41% (Fig. 2). This indicated the presence of more than one vaccine variant in each specimen. 
Likewise, Loparev and coauthors reported on the presence of more than one vaccine variant in 
specimens from vaccinees. In accordance with our results (on average, 54% vaccine, 34% wt, and 
12% mixed markers), these authors observed 59% vaccine, 33% wt, and 8% mixed markers in 
vaccine-related rashes (9).  
Finally, PSQ of wt VZV from nonvaccinated (n = 4) and vaccinated (n = 5) individuals uniformly 
revealed alleles at all 32 SNP positions that had been defined as wt on the basis of the sequences of 
wt strains Oka-P and Dumas (Fig. 1). This showed that there is most likely no variation among wt 
strains in the 32 SNPs analyzed in this study (Fig. 1).  
Comparison of orf62 sequences from vaccines with those from vaccinees suffering from 
rashes. To determine whether vaccine-type VZV strains in patient specimens are genetically identical 
to vaccine-type VZV strains present as minorities in vaccines, we examined orf62, which encodes a 
transactivator protein thought to contribute to the attenuation of the vaccine (4, 5). orf62 encompasses 
more than one-third of the SNPs analyzed here and therefore is a highly representative locus in the 
genome. To analyze SNP profiles of single molecules, we cloned the entire orf62 in E. coli. Clones 
from the three vaccines were completely sequenced by CTSQ, and 11 SNP positions were analyzed. 
It appeared that Varivax contains a larger diversity of VZV variant strains than Varilrix and Priorix-
Tetra. Thirty different SNP profiles were observed for Varivax and only 10 were observed for Varilrix 
and Priorix-Tetra (Fig. 4A and B, respectively). Furthermore, the Varivax variant strains on average 
contained more wt SNPs (37%; Fig. 4A) than the variant strains of Varilrix and Priorix-Tetra (17%; Fig. 
4B). In addition, the SNP profiles of the cloned vaccine variant orf62 sequences were compared with 
the profiles of the vaccine-type VZV in the nine patient specimens with vaccine-type VZV. Importantly, 
one or more vaccine clone profiles were identical to one of the orf62 profiles originating from the 
specimens and were almost exclusively detected in Varivax (Fig. 3). It has previously been speculated 
(but not formally demonstrated) that the vaccine VZV variants detected in patient specimens preexist 
in the administered vaccine preparations (9, 10). Our data are the first to indicate that this is most 
likely the case (Fig. 3). However, our analysis was restricted to orf62, which covers only one-third of 
the SNPs differentiating vaccine strains from the parent wt strain Oka-P. Further analysis of complete 
genomes is required to settle this issue.  
SNPs for diagnostic differentiation of wild-type versus vaccine-type VZV. Different commercial 
preparations of varicella vaccine (Varilrix and Priorix-Tetra, both from GSK; Varivax from SPMSD) 
were compared by PSQ for the first time. Due to the higher sensitivity of PSQ than CTSQ, 
unprecedentedly high percentages of mixed SNPs were found in VZV strains in all three vaccine 
brands. However, even SNPs that were found by PSQ to be pure vaccine type and that had previously 
been reported to be pure (7, 9, 10) revealed very low levels of wt SNPs when larger numbers of E. coli 
clones were analyzed (Fig. 1). Four SNPs (nt 105705, 106262, 107252, and 108111) have formerly 
been reported to be pure vaccine type in vaccines and individuals with vaccine-related rashes (7, 9, 
  
10). One of them, nt 106262, has been used in real-time PCR to firmly discriminate wt strains from 
vaccine strains (8). In this study, we detected 5 to 6% wt SNPs at two of the four positions (nt 106262 
and 108111) by PSQ of a large number of E. coli clones of the vaccine Varivax VZV (Fig. 1). In 
addition, a complete orf62 of Varivax VZV was cloned in E. coli and revealed the wt allele at position 
108111 (Fig. 4A). Of note, wt alleles were previously detected by CTSQ at positions 560, 105705, 
107252, and 108111 in VZV strains from some older lots of Varilrix. In contrast, Varivax lots revealed 
VZV strains with pure vaccine types at these positions (13, 14). These data and those presented here 
show that the mixtures of variant strains in the vaccines as well as the relative strain proportions 
change with time in different vaccine batches. It is therefore reasonable to assume that the SNP 
profiles of vaccine-type VZV strains causing rash-like illnesses in vaccinees may change over time as 
well. On the basis of this assumption, the firm discrimination of vaccine-type VZV from wt VZV strains 
should include more than one SNP. Rather, the four-position core set (nt 105705, 106262, 107252, 
and 108111) should be used for diagnostic differentiation of wild-type and vaccine-type VZV.  
Conclusions. In this study of VZV variants, mixed alleles with small wt minorities were detected with a 
high sensitivity by PSQ. While CTSQ usually does not detect allele or mutant minorities present at 
levels below 20% in mixed alleles (2, 15), most PSQ assays detect them with a detection limit well 
below 10% (15; this study). Furthermore, alleles can be quantified by PSQ, in contrast to CTSQ. An 
additional advantage is that PSQ is much faster than CTSQ, enabling the analysis of 96 PCR products 
in 10 min. By PSQ, we determined an estimated 3-fold higher diversity of VZV variants with 20% more 
wt SNPs in Varivax than Varilrix and Priorix-Tetra. Furthermore, by analyzing the complete orf62, we 
observed VZV variants that represented minor components of the Varivax vaccine in vaccinated 
individuals suffering from mild rash-associated syndromes. Therefore, Varivax resembles a vaccine 
that appears to have more “wild-type-like” VZV. This might be the reason why Varivax, on the one 
hand, seems to be related to comparatively higher frequencies of rash-associated syndromes, i.e., 
mild forms of varicella or zoster, and, on the other hand, protects against varicella more efficiently. In 
the future, the ongoing German varicella sentinel will provide further insight into this issue. Finally, 
from our PSQ data on vaccine virus cloned in E. coli, it is concluded that the analysis of a core set of 
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Table 1.  Long-distance PCR primer sets 
 
a s, sense; as, antisense.  






















Table 2.  PCR plus PSQ primer sets 
 
 
a s, sense; as, antisense; NCR, noncoding region.  
b bio, biotin.  




Figure 1. VZV SNPs determined by PCR and PSQ. SNPs (n = 32) from nine patients with vaccine-
type VZV, four nonvaccinated and five vaccinated patients with wild-type VZV, and VZV from the three 
vaccine brands are shown. The corresponding SNPs of Varivax and Varilrix VZV, the original vaccine 
strain Oka-V, and wt strains Oka-P and Dumas are included for comparison. The last two lines show 
the percentages of wt markers (positions 560, 105310, 106262, 107136, and 108111) and of vaccine-
type markers (positions nt 105544, 105705, and 107252) that were revealed by PSQ of E. coli clones. 






Figure 2. Percentage of markers detected in the nine specimens from vaccine-associated rashes. For 
each specimen, 32 SNP positions were analyzed by PSQ. Red bars, wt markers; blue bars, vaccine 











Figure 3.  SNPs in the orf62 sequences of nine vaccine-type VZV strains from vaccinees with rashes. 
The orf62 sequences were amplified with LD-PCR and completely sequenced (chain termination 
sequencing). Twelve SNP positions are compared with orf62 clone sequences from Varivax VZV (n = 
16) and Priorix-Tetra VZV (n = 1). Red boxes, wt markers; blue boxes, vaccine markers; yellow boxes, 



















Figure 4. SNPs in the orf62 sequences of individual vaccine VZV genomes from three varicella 
vaccines. SNPs were determined from individual E. coli clones of complete orf62 sequences from 
Varivax VZV (A) and Varilrix and Priorix-Tetra VZV (B) with CTSQ. Red boxes, wt markers; blue 
boxes, vaccine markers; yellow boxes, mixed markers. Note the wt allele at position 108111 in clone 













Figure 5.  Percentage of wild-type markers determined by PSQ for 32 SNPs of vaccine VZV genomes 
from three varicella vaccines. The vertical bars indicate the individual detection limits. They were 
defined as described in the text. Black bars, Varivax; white bars, Varilrix; hatched bars, Priorix-Tetra.  
 
 
  
